Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mechanisms of VSM dysfunction in diabetes and HFpEF

Award Number: R01HL171014
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/15/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2027

Group Awards By:

View Award Description

Mechanisms of VSM dysfunction in diabetes and HFpEF - Abstract . Vascular complications associated with lifestyle-related diseases, such as diabetes, contribute to an increased risk of hypertension, coronary artery disease, and heart failure associated with preserved ejection fraction (HFpEF). These vascular complications may involve, at least in part, vascular smooth muscle (VSM) dysfunction leading to impaired vasomotor function, but mechanisms remain poorly understood. We recently identified a novel AKAP5/P2Y11/AC5/PKA/CaV1.2 nanocomplex that is activated by the release of extracellular nucleotides, such as ATP. This complex controls VSM contractility, vasoconstriction, and altered blood flow (BF) and blood pressure (BP) in response to elevated extracellular glucose (e.g. hyperglycemia; HG – a major metabolic abnormality in diabetes). Yet, whether HG stimulates cellular nucleotide release, the precise molecular entity underlying this process, and its potential role in diabetes and other diseases (e.g. HFpEF) are unknown. The overarching goal of this MPI proposal is to provide insight into these issues. Our preliminary data offers a unique window into these queries and uncover an essential role for the large-pore channel pannexin 1 (Panx1) as a key member and upstream protein activating the nanocomplex and thus contributing to altered vascular reactivity during diabetes and perhaps other diseases such as HFpEF. We will address the novel central hypothesis that Panx1 is upstream and part of the AKAP5/P2Y11/AC5/PKA/CaV1.2 signaling axis that promotes VSM contractility and altered BF/BP in response to diabetic hyperglycemia. The proposal has high significance as it defines Panx1 as 1) a key upstream pathway triggering pathological signaling resulting in VSM hypercontractility during diabetic hyperglycemia and 2) a potential therapeutic target to treat vascular complications in diabetes (and perhaps HFpEF). The influence of Panx1 in contributing to the ATP release in response to HG, and in strengthening/weakening the formation of nanocomplexes to mediate functional responses, which may have broader implications in any Panx1-dependent signaling process, is an emerging and innovative concept. Our innovative multi-scale approach using state-of-the-art approaches will be implemented to explore the following aims. Aim 1 is to elucidate the role of Panx1 on HG signaling in VSM. Aim 2 is to determine the impact of Panx1 on VSM dysfunction during diabetes and HFpEF. The impact of the proposal is in establishing Panx1 as a key contributor to defective VSM function and vascular complications in diabetes and HFpEF.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $681,632 )
2026	2026	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	001	3	3/24/2026	NON-COMPETING CONTINUATION	$20,867
2026	2026	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	000	3	2/10/2026	NON-COMPETING CONTINUATION	$660,765
														Subtotal = $681,632

Issue Date FY: 2025 ( Subtotal = $695,543 )
2025	2025	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	000	2	11/18/2024	NON-COMPETING CONTINUATION	$625,989
2025	2025	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	001	2	7/25/2025	NON-COMPETING CONTINUATION	$69,554
														Subtotal = $695,543

Issue Date FY: 2024 ( Subtotal = $666,922 )
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	000	1	12/6/2023	NEW	$623,721
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cardiovascular Diseases Research	001	1	6/21/2024	NEW	$43,201
														Subtotal = $666,922

Grand Total All Awards = $2,044,097

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanisms of VSM dysfunction in diabetes and HFpEF

Award Number: R01HL171014

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/15/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer